Founded by dermatologists, Veradermics leverages its front-line clinical experience to identify and advance novel drugs that address specific patient needs and solve pervasive treatment challenges in dermatology practice. The company has cultivated a pipeline of diverse, first-in-class, single-molecule therapeutics for highly prevalent dermatologic conditions seen in adults and children. Target indications include common warts (verruca vulgaris), alopecia areata, molluscum contagiosum, androgenetic alopecia (pattern hair loss), and atopic dermatitis. Veradermics’ lead product candidate, VDMN, offers a new, patient-friendly, injection-free approach for the treatment of common warts. Veradermics is led by an executive team of board-certified dermatologists supported by a board of directors comprised of recognized biopharmaceutical industry leaders.